NHD Global
Longevity & Bioregulators · Source-reviewed dossier
Source-Reviewed Research Dossier
PNC-27 is a synthetic peptide studied in cancer-cell experiments. Linked pancreatic- and cervical-cell studies reported cell damage associated with HDM-2, a protein found on the cell surface in those experiments. Researchers also examined holes in cell membranes and changes in mitochondria, structures involved in energy production. Responses differed between the particular cell lines compared. These are laboratory findings, not cancer-treatment results in patients or proof of safety across healthy tissues. NHD supplies PNC-27 for research use.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2024 study evaluated PNC-27 interactions and cytotoxicity in experimental cancer systems.
Laboratory cytotoxicity does not establish a therapeutic window in humans.
Read the primary studyA 2025 report investigated PNC-27 in additional experimental tumor models.
Model-specific antitumor findings require independent clinical validation.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Laboratory cytotoxicity does not establish a therapeutic window in humans.
View primary recordModel-specific antitumor findings require independent clinical validation.
View primary recordThird-party publications selected for direct relevance.
Preclinical study. 2024. PMID 38802154.
Preclinical study. 2025. PMID 40750238.
Concise answers for researchers comparing identity, evidence and catalog variants.
In pancreatic- and cervical-cancer cell experiments, PNC-27 killed cancer cells in dishes. This was linked to HDM-2 on the cell surface. Researchers also looked at pore formation and mitochondrial disruption. These are cell-culture results, not cancer-treatment outcomes in people. They do not show that PNC-27 works or is safe in humans.
In cervical-cell experiments, PNC-27 killed cancer cells but not untransformed cervical cells from the same tissue. The cancer cells also had more HDM-2 on their surface. This is a controlled laboratory comparison, not proof of selectivity in every tumour or healthy tissue. Whether the peptide reaches tumours and is safe in living systems remains a separate, unanswered question.
Recent records continue to be preclinical; controlled human trial evidence was not identified.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
A K562 cell experiment reported extensive cell killing. Learn what the measurements show and why they do not establish a cancer treatment.
Updated October 10, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: PNC10 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
